1-naphthylsulfamic acid | 24344-19-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-naphthylsulfamic acid
• 英文别名: [1]naphthyl-amidosulfuric acid；[1]Naphthyl-amidoschwefelsaeure；Naphthyl-(1)-sulfamidsaeure；α-Naphthyl-sulfamidsaeure；naphthylaminesulphonic acid；naphthylamino-sulfonic acid；Naphthalen-1-ylsulfamic acid
• CAS: 24344-19-2
• 化学式: C₁₀H₉NO₃S
• 分子量: 223.252
• InChiKey: XFSXWFOXECTCPD-UHFFFAOYSA-N

物化性质

• 密度：
  1.539±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-naphthylsulfamic acid 、 2-萘酚 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Quilico, Gazzetta Chimica Italiana, 1926, vol. 56, p. 626

  摘要：

  DOI：
• 作为产物：
  描述：

  1-萘胺 在 氯磺酸 、 氯仿 作用下， 生成 1-naphthylsulfamic acid
  参考文献：
  名称：

  DE79132

  摘要：

  公开号：

文献信息

• [EN] DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS<br/>[FR] DÉRIVÉS DE DIAZABICYCLO[4.3.1]DÉCANE POUR LE TRAITEMENT DE TROUBLES PSYCHIATRIQUES
  申请人：MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V

  公开号：WO2015110271A1

  公开（公告）日：2015-07-30

  The present invention relates to diazabicyclo[4.3.1 ]decane derivatives (I), pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives are specific inhibitors of the FK506 binding proteins (FKBP's) and can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

  本发明涉及二氮杂双环[4.3.1]癸烷衍生物(I)，这些化合物的药用盐以及含有至少一种这些化合物的药用载体、赋形剂和/或稀释剂的药物组合物。所述的二氮杂双环[4.3.1]癸烷衍生物是FK506结合蛋白(FKBP)的特异性抑制剂，可用于预防和/或治疗精神障碍和神经退行性疾病、障碍和症状。
• Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2899192A1

  公开（公告）日：2015-07-29

  The present invention relates to diazabicyclo[4.3.1]decane derivatives of formula (I), pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives are inhibitors of the FK506 binding protein (FKBP's) and can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

  本发明涉及式(I)的二氮杂双环[4.3.1]癸烷衍生物，这些化合物的药用盐以及含有至少一种这些化合物的药用载体、赋形剂和/或稀释剂的药物组合物。所述的二氮杂双环[4.3.1]癸烷衍生物是FK506结合蛋白（FKBP's）的抑制剂，可用于预防和/或治疗精神障碍和神经退行性疾病、障碍和症状。
• DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

  公开号：US20170002003A1

  公开（公告）日：2017-01-05

  The present invention relates to diazabicyclo[4.3.1]decane derivatives, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

  本发明涉及二氮杂双环[4.3.1]癸烷衍生物，这些化合物的药用盐以及含有至少一种这些化合物的药用载体、赋形剂和/或稀释剂的药物组合物。所述的二氮杂双环[4.3.1]癸烷衍生物可用于预防和/或治疗精神障碍和神经退行性疾病、障碍和症状。
• Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2851092A1

  公开（公告）日：2015-03-25

  The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.

  本发明提供了一种不含蛋白质和多肽的缀合物，该缀合物包括一种合成碳水化合物和一个载体分子，其中合成碳水化合物是与肺炎链球菌3型荚膜多糖相关的碳水化合物，载体分子是一种糖鞘脂。所述缀合物及其药物组合物可用于免疫预防与肺炎链球菌相关的疾病，特别是与肺炎链球菌3型相关的疾病。
• Pyridazinones for the treatment of cancer
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2955182A1

  公开（公告）日：2015-12-16

  The present invention relates to novel substituted pyrrolo- and pyrazolopyridazinones, as well as pharmaceutical compositions containing at least one of these substituted pyrrolo- and pyrazolo- pyridazinones together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said novel substituted pyrrolo- and pyrazolo- pyridazinones are binding to the prenyl binding pocket of PDEδ and therefore, are useful for the prophylaxis and treatment of cancer by inhibition of the binding of PDEδ to K-Ras and of Ras signaling in cells.

  本发明涉及新型取代吡咯并吡唑吡啶酮，以及含有至少一种这些新型取代吡咯并吡唑吡啶酮的药物组合物，该药物组合物还包括至少一种药用可接受的载体、赋形剂和/或稀释剂。所述新型取代吡咯并吡唑吡啶酮结合到PDEδ的藤黄素结合口袋，因此，通过抑制PDEδ与K-Ras的结合以及细胞中Ras信号传导的结合，对癌症的预防和治疗具有用处。